Preprint · CC-BY
via bioRxiv
Engineering BCMA CAR T cells for myeloma-targeted cargo delivery
Kimman, T., Cuenca, M., Slomp, A., Tieland, R. G., Rockx-Brouwer, D., Heijhuurs, S., Meringa, A. D., Boschloo, W., Bosma, D. M., Kroos, S., lo Presti, V., Nierkens, S., Bovenschen, N., Kuball, J., Minnema, M. C.
biorxiv · 2024
Abstract
Clinical responses with chimeric antigen receptor (CAR) T cells are encouraging, however, primary resistance and relapse after therapy prevent durable remission in a large fraction of cancer patients. One of the underlying causes comprises apoptosis resistance mechanisms in cancer cells that limit killing by CAR T cells. Therefore, we developed a technology that boosts tumor cell apoptosis induced by CAR T cells. We reveal that B cell maturation antigen (BCMA) CAR T cells equipped with a granzyme B-NOXA fusion construct improves killing of multiple myeloma (MM) cells, both in vitro and in a xenograft mouse model, by localizing NOXA to cytotoxic granules that are released into cancer cells upon contact. Since MM cells critically depend on MCL-1 expression, inhibition by its natural ligand NOXA effectively induces apoptosis. Overall, this strategy allows specific delivery of cargo into cancer cells and improves killing efficacy of CAR T cells in a tailor-made manner.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- bioRxiv
- DOI
- 10.1101/2024.02.14.580301
- Canonical
- link ↗
- Fetched
- 2026-10-11 MST
Cite this
APA
T., K., M., C., A., S., G., T.R., D., R., S., H., D., M.A., W., B., M., B.D., S., K., V., L.P., S., N., N., B., J., K., C., M.M., Z., S., & V., P. (2024). Engineering BCMA CAR T cells for myeloma-targeted cargo delivery. <em>biorxiv</em>. https://doi.org/10.1101/2024.02.14.580301
Vancouver
T. K, M. C, A. S, G. TR, D. R, S. H, et al. Engineering BCMA CAR T cells for myeloma-targeted cargo delivery. biorxiv. 2024. doi:10.1101/2024.02.14.580301.
BibTeX
@unpublished{kimman2024Engine,
title = {Engineering BCMA CAR T cells for myeloma-targeted cargo delivery},
author = {Kimman, T. and Cuenca, M. and Slomp, A. and Tieland, R. G. and Rockx-Brouwer, D. and Heijhuurs, S. and Meringa, A. D. and Boschloo, W. and Bosma, D. M. and Kroos, S. and lo Presti, V. and Nierkens, S. and Bovenschen, N. and Kuball, J. and Minnema, M. C. and Sebestyen, Z. and Peperzak, V.},
journal = {biorxiv},
year = {2024},
doi = {10.1101/2024.02.14.580301},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Journal of Hematology & Oncology 2022
Open access · OA
Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management
Anticancer Research 2024
Open access · CC-BY
Genotoxic and Cytotoxic Activity of Fisetin on Glioblastoma Cells
Cellular and Molecular Life Sciences 2019
Open access · CC-BY
Mechanisms of secretion and spreading of pathological tau protein
JNCI Journal of the National Cancer Institute 2021
Open access · CC-BY
Therapy-Induced Senescence: Opportunities to Improve Anticancer Therapy
Mechanisms of Ageing and Development 2021
Citation only
The Spt7 subunit of the SAGA complex is required for the regulation of lifespan in both dividing and nondividing yeast cells
Oncology Reports 2018
Open access · OA